Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV's positive outlook is bolstered by a significant increase in peak revenue estimates for its gene therapy AMT-130 for Huntington's disease, projected to reach approximately $3 billion. The company has demonstrated a favorable safety profile for AMT-130, alongside sustained efficacy and biomarker improvements, which solidify its potential as the first disease-modifying treatment for Huntington's disease. Furthermore, the commercial infrastructure appears well-prepared to facilitate a robust launch in 2026, indicating strong future market entry capabilities.

Bears say

uniQure NV's financial outlook appears negative due to the company’s reliance on a high-risk gene therapy pipeline, especially for complex diseases such as Huntington's disease and cardiovascular conditions. Despite presenting statistically significant results in clinical trials, such as a 75% slowing of decline in neuromarkers, the long-term commercial viability and reimbursement potential of these therapies remain uncertain. Moreover, the collaboration with Bristol Myers Squibb may not sufficiently mitigate financial risks associated with research and development expenditures inherent in the gene therapy sector.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.